Table 1.

Patient Demographics According to Country.

Variables	Canada (Toronto Western Hospital, Toronto, Canada)	Kuwait (Al-Amiri Hospital, Kuwait City, Kuwait)	Saudi Arabia (King Abdulaziz University, Jeddah, Saudi Arabia)	Australia (Austin and Western Health, University of Melbourne, Australia)	Total
Number of responders	80	20	33	29	162
Duration of InterStim
• 1–3 mo	4 (5%)	2 (10%)	1 (3%)	5 (17%)	12 (7.4%)
• >3 mo	76 (95%)	18 (90%)	32 (96.9%)	24 (82.7%)	150 (92.5%)
Reason for SNM
• OAB	38 (47.5%)	9 (45%)	16 (48%)	21 (72%)	84 (51%)
• Retention	27 (33.75%)	9 (45%)	11 (33%)	7 (24%)	54 (33%)
• IC	8 (10%)	2 (10%)	5 (15%)	1 (3%)	16 (9%)
• Fecal incontinence	5 (6.25%)	0 (0%)	1 (3%)	0 (0%)	6 (3%)
• OAB + fecal incontinence	2 (2.5%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)
Postoperative complication
• None	54 (67.5%)	16 (80%)	31 (93%)	20 (69%)	121 (74.6%)
• Pain	13 (16.25%)	3 (15%)	0 (0%)	4 (13.7%)	20 (12.3%)
• Malfunction	7 (8.75%)	1 (5%)	2 (6%)	3 (10%)	13 (8%)
• Bleeding	1 (1.25%)	0 (0%)	0 (0%)	0 (0%)	1 (0.6%)
• Infection	5 (6.25%)	0 (0%)	0 (0%)	2 (6.8%)	7 (4.3%)
Use the device easily
• All the time	64 (80%)	16 (80%)	23 (70%)	19 (65%)	122 (75%)
• Most of the time	15 (18.75%)	2 (10%)	10 (30%)	8 (27%)	35 (21%)
• Sometimes	1 (1.25%)	1 (5%)	0 (0%)	1 (3.4%)	3 (1.8%)
• No	0 (0%)	1 (5%)	0 (0%)	1 (3.4%)	2 (1%)
Improvement rate
• >80	28 (35%)	14 (70%)	0 (0%)	1 (3.4%)	43 (26%)
• <50	7 (8.75%)	1 (5%)	0 (0%)	6 (20%)	14 (8.6%)
• 50–80	45 (56.25%)	5 (25%)	33 (100%)	22 (75%)	105 (64%)
COVID-19 diagnosis
• Positive	0 (0%)	0 (0%)	2 (6%)	NA	2 (1.23%)
• Negative	80 (100%)	20 (100%)	31 (93.9%)	NA	131 (80%)

IC, interstitial cystitis; NA, not available; OAB, overactive bladder.